| [1] |
Hoste EAJ, Kellum JA, Selby NM, et al. Global epidemiology and outcomes of acute kidney injury [J]. Nat Rev Nephrol, 2018, 14(10): 607-625.
|
| [2] |
Kellum JA, Romagnani P, Ashuntantang G, et al. Acute kidney injury [J]. Nat Rev Dis Primers, 2021, 7(1): 52.
|
| [3] |
Khwaja A. KDIGO clinical practice guidelines for acute kidney injury [J]. Nephron Clin Pract, 2012, 120(4): c179-c184.
|
| [4] |
Schrezenmeier EV, Barasch J, Budde K, et al. Biomarkers in acute kidney injury-pathophysiological basis and clinical performance [J]. Acta Physiol (Oxf), 2017, 219(3): 554-572.
|
| [5] |
Zhang A, Cai Y, Wang P-F, et al. Diagnosis and prognosis of neutrophil gelatinase-associated lipocalin for acute kidney injury with sepsis: a systematic review and meta-analysis [J]. Crit Care, 2016, 20(1): 41.
|
| [6] |
Jahaj E, Vassiliou AG, Pratikaki M, et al. Serum neutrophil gelatinase-associated lipocalin (NGAL) could provide better accuracy than creatinine in predicting acute kidney injury development in critically ill patients [J]. J Clin Med, 2021, 10(22): 5379.
|
| [7] |
Yi A, Lee C-H, Yun Y-M, et al. Effectiveness of plasma and urine neutrophil gelatinase-associated lipocalin for predicting acute kidney injury in high-risk patients [J]. Ann Lab Med, 2021, 41(1): 60-67.
|
| [8] |
Huelin P, Solà E, Elia C, et al. Neutrophil gelatinase-associated lipocalin for assessment of acute kidney injury in cirrhosis: a prospective study [J]. Hepatology, 2019, 70(1): 319-333.
|
| [9] |
Ye Z, Liu H, Zhao B, et al. Correlation and diagnostic value of serum Cys-C, RBP4, and NGAL with the condition of patients with traumatic acute kidney injury [J]. Evid Based Complement Alternat Med, 2021, 2021: 4990941.
|
| [10] |
Andrade L, Rodrigues CE, Gomes SA, et al. Acute kidney injury as a condition of renal senescence [J]. Cell Transplant, 2018, 27(5): 739-753.
|
| [11] |
Kashani K, Al-Khafaji A, Ardiles T, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury [J]. Crit Care, 2013, 17(1): R25.
|
| [12] |
Bihorac A, Chawla LS, Shaw AD, et al. Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication [J]. Am J Respir Crit Care Med, 2014, 189(8): 932-939.
|
| [13] |
Heung M, Ortega LM, Chawla LS, et al. Common chronic conditions do not affect performance of cell cycle arrest biomarkers for risk stratification of acute kidney injury [J]. Nephrol Dial Transplant, 2016, 31(10): 1633-1640.
|
| [14] |
Fiorentino M, Xu Z, Smith A, et al. Serial measurement of cell-cycle arrest biomarkers [TIMP-2]·[IGFBP7]and risk for progression to death, dialysis, or severe acute kidney injury in patients with septic shock [J]. Am J Respir Crit Care Med, 2020, 202(9): 1262-1270.
|
| [15] |
Jia H-M, Huang L-F, Zheng Y, et al. Prognostic value of cell cycle arrest biomarkers in patients at high risk for acute kidney injury: a systematic review and meta-analysis [J]. Nephrology, 2017, 22(11): 831-837.
|
| [16] |
Johnson ACM, Zager RA. Mechanisms underlying increased TIMP2 and IGFBP7 urinary excretion in experimental AKI [J]. J Am Soc Nephrol, 2018, 29(8): 2157-2167.
|
| [17] |
Daubin D, Cristol JP, Dupuy AM, et al. Urinary biomarkers IGFBP7 and TIMP-2 for the diagnostic assessment of transient and persistent acute kidney injury in critically ill patients [J]. PLoS One, 2017, 12(1): e0169674.
|
| [18] |
Titeca-Beauport D, Daubin D, Van Vong L, et al. Urine cell cycle arrest biomarkers distinguish poorly between transient and persistent AKI in early septic shock: a prospective, multicenter study [J]. Crit Care, 2020, 24(1): 280.
|
| [19] |
Karmakova ТА，Sergeeva NS, Kanukoev КY, et al. Kidney injury molecule 1 (KIM-1): a multifunctional glycoprotein and biological marker [J]. Sovrem Tekhnologii Med, 2021, 13(3): 64-78.
|
| [20] |
Zhou Y, Vaidya VS, Brown RP, et al. Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium [J]. Toxicol Sci, 2008, 101(1): 159-170.
|
| [21] |
Shinke H, Masuda S, Togashi Y, et al. Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients [J]. Cancer Chemother Pharmacol, 2015, 76(5): 989-996.
|
| [22] |
Geng J, Qiu Y, Qin Z, et al. The value of kidney injury molecule 1 in predicting acute kidney injury in adult patients: a systematic review and Bayesian meta-analysis [J]. J Transl Med, 2021, 19(1): 105.
|
| [23] |
Ganda IJ, Kasri Y, Susanti M, et al. Kidney injury molecule type-1, interleukin-18, and insulin-like growth factor binding protein 7 levels in urine to predict acute kidney injury in pediatric sepsis [J]. Front Pediatr, 2022, 10: 1024713.
|
| [24] |
Xie Y, Wang Q, Wang C, et al. High urinary excretion of kidney injury molecule-1 predicts adverse outcomes in acute kidney injury: a case control study [J]. Crit Care, 2016, 20(1): 286.
|
| [25] |
Kwon T-J, Jang E, Lee D-S, et al. Development of a noninvasive KIM-1-based live-imaging technique in the context of a drug-induced kidney-injury mouse model [J]. ACS Appl Bio Mater, 2021, 4(2): 1508-1514.
|
| [26] |
Yanishi M, Kinoshita H. Urinary L-type fatty acid-binding protein is a predictor of cisplatin-induced acute kidney injury [J]. BMC Nephrol, 2022, 23(1): 125.
|
| [27] |
Lee TH, Lee CC, Chen JJ, et al. Assessment of cardiopulmonary bypass duration improves novel biomarker detection for predicting postoperative acute kidney injury after cardiovascular surgery [J]. J Clin Med, 2021, 10(13): 2741.
|
| [28] |
Naruse H, Ishii J, Takahashi H, et al. Predicting acute kidney injury using urinary liver-type fatty-acid binding protein and serum N-terminal pro-B-type natriuretic peptide levels in patients treated at medical cardiac intensive care units [J]. Crit Care, 2018, 22(1): 197.
|
| [29] |
Naruse H, Ishii J, Takahashi H, et al. Urinary liver-type fatty-acid-binding protein predicts long-term adverse outcomes in medical cardiac intensive care units [J]. J Clin Med, 2020, 9(2): 482.
|
| [30] |
Torigoe K, Muta K, Tsuji K, et al. Urinary liver-type fatty acid-binding protein predicts residual renal function decline in patients on peritoneal dialysis [J]. Med Sci Monit, 2020, 26: e928236.
|
| [31] |
Thi TND, Gia BN, Thi HLL, et al. Evaluation of urinary L-FABP as an early marker for diabetic nephropathy in type 2 diabetic patients [J]. J Med Biochem, 2020, 39(2): 224-230.
|
| [32] |
Juanola A, Graupera I, Elia C, et al. Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis [J]. J Hepatol, 2022, 76(1): 107-114.
|
| [33] |
Beker BM, Corleto MG, Fieiras C, et al. Novel acute kidney injury biomarkers: their characteristics, utility and concerns [J]. Int Urol Nephrol, 2018, 50(4): 705-713.
|
| [34] |
Lin X, Yuan J, Zhao Y, et al. Urine interleukin-18 in prediction of acute kidney injury: a systemic review and meta-analysis [J]. J Nephrol, 2015, 28(1): 7-16.
|
| [35] |
Liu Y, Guo W, Zhang J, et al. Urinary interleukin 18 for detection of acute kidney injury: a meta-analysis [J]. Am J Kidney Dis, 2013, 62(6): 1058-1067.
|
| [36] |
Nisula S, Yang R, Poukkanen M, et al. Predictive value of urine interleukin-18 in the evolution and outcome of acute kidney injury in critically ill adult patients [J]. Br J Anaesth, 2015, 114(3): 460-468.
|
| [37] |
Gonul Y, Kazand S, Kocak A, et al. Interleukin-18 binding protein pretreatment attenuates kidney injury induced by hepatic ischemia reperfusion [J]. Am J Med Sci, 2016, 352(2): 200-207.
|
| [38] |
Wu YL, Li HF, Chen HH, et al. MicroRNAs as biomarkers and therapeutic targets in inflammation- and ischemia-reperfusion-related acute renal injury [J]. Int J Mol Sci, 2020, 21(18): 6738.
|
| [39] |
Wei Q, Bhatt K, He HZ, et al. Targeted deletion of Dicer from proximal tubules protects against renal ischemia-reperfusion injury [J]. J Am Soc Nephrol, 2010, 21(5): 756-761.
|
| [40] |
Guo C, Dong G, Liang X, et al. Epigenetic regulation in AKI and kidney repair: mechanisms and therapeutic implications [J]. Nat Rev Nephrol, 2019, 15(4): 220-239.
|
| [41] |
Liu Z, Yang D, Gao J, et al. Discovery and validation of miR-452 as an effective biomarker for acute kidney injury in sepsis [J]. Theranostics, 2020, 10(26): 11963-11975.
|
| [42] |
Aomatsu A, Kaneko S, Yanai K, et al. MicroRNA expression profiling in acute kidney injury [J]. Transl Res, 2022, 244: 1-31.
|
| [43] |
Wilflingseder J, Jelencsics K, Bergmeister H, et al. MiR-182-5p inhibition ameliorates ischemic acute kidney injury [J]. Am J Pathol, 2017, 187(1): 70-79.
|
| [44] |
Cao JY, Wang B, Tang TT, et al. Exosomal miR-125b-5p deriving from mesenchymal stem cells promotes tubular repair by suppression of p53 in ischemic acute kidney injury [J]. Theranostics, 2021, 11(11): 5248-5266.
|
| [45] |
Li X, Liao J, Su X, et al. Human urine-derived stem cells protect against renal ischemia/reperfusion injury in a rat model via exosomal which targets [J]. Theranostics, 2020, 10(21): 9561-9578.
|
| [46] |
Neyra JA, Hu MC, Moe OW. Klotho in clinical nephrology: diagnostic and therapeutic implications [J]. Clin J Am Soc Nephrol, 2020, 16(1): 162-176.
|
| [47] |
Neyra JA, Hu MC, Moe OW. Fibroblast growth factor 23 and αklotho in acute kidney injury: current status in diagnostic and therapeutic applications [J]. Nephron, 2020, 144(12): 665-672.
|
| [48] |
Hu MC, Shi M, Zhang J, et al. Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective [J]. Kidney Int, 2010, 78(12): 1240-1251.
|
| [49] |
王顺，杨磊，刘健，等. 血清Klotho蛋白监测对急性肾损伤早期诊断及预后评估的价值 [J]. 中华肾脏病杂志，2018, 34(2): 94-98.
|
| [50] |
Qian Y, Che L, Yan Y, et al. Urine klotho is a potential early biomarker for acute kidney injury and associated with poor renal outcome after cardiac surgery [J]. BMC Nephrol, 2019, 20(1): 268.
|
| [51] |
Shi M, Flores B, Gillings N, et al. αKlotho mitigates progression of AKI to CKD through activation of autophagy [J]. J Am Soc Nephrol, 2016, 27(8): 2331-2345.
|
| [52] |
Christov M, Neyra JA, Gupta S, et al. Fibroblast growth factor 23 and klotho in AKI [J]. Semin Nephrol, 2019, 39(1): 57-75.
|
| [53] |
Zhu X, Li S, Lin Q, et al. αKlotho protein has therapeutic activity in contrast-induced acute kidney injury by limiting NLRP3 inflammasome-mediated pyroptosis and promoting autophagy [J]. Pharmacol Res, 2021, 167: 105531.
|
| [54] |
Ostermann M, Zarbock A, Goldstein S, et al. Recommendations on acute kidney injury biomarkers from the acute disease quality initiative consensus conference: a consensus statement [J]. JAMA Netw Open, 2020, 3(10): e2019209.
|